

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM428859

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT		05/04/2017	National Association: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	ACORDA THERAPEUTICS, INC.		
<b>Street Address:</b>	420 Saw Mill River Road		
<b>City:</b>	Arddley		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10502		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	CIVITAS THERAPEUTICS, INC.		
<b>Street Address:</b>	420 Saw Mill River Road		
<b>City:</b>	Ardsley		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10502		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	NEURONEX, INC.		
<b>Street Address:</b>	420 Saw Mill River Road		
<b>City:</b>	Ardsley		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10502		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 8</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2383531	ZANAFLEX	
<b>Registration Number:</b>	2913451	ACORDA THERAPEUTICS	
<b>Registration Number:</b>	3719009	QUTENZA	
<b>Registration Number:</b>	3565849	ACORDA THERAPEUTICS	
<b>Registration Number:</b>	3341341	ZANAFLEX CAPSULES	
<b>Registration Number:</b>	3878204	NEUROGESX	
<b>TRADEMARK</b>			

Property Type	Number	Word Mark
Registration Number:	3786343	NEUROGESX
Registration Number:	4217046	ARCUS

**CORRESPONDENCE DATA**

**Fax Number:** 6173417729

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 6173417729

**Email:** katarzyna.gaysunas@morganlewis.com

**Correspondent Name:** Katarzyna Gaysunas

**Address Line 1:** 1 Federal Street

**Address Line 2:** c/o Morgan, Lewis & Bockius LLP

**Address Line 4:** Boston, MASSACHUSETTS 02110

<b>NAME OF SUBMITTER:</b>	Katarzyna Gaysunas
---------------------------	--------------------

<b>SIGNATURE:</b>	/Katarzyna Gaysunas/
-------------------	----------------------

<b>DATE SIGNED:</b>	05/22/2017
---------------------	------------

**Total Attachments: 6**

source=Trademark Termination#page1.tif

source=Trademark Termination#page2.tif

source=Trademark Termination#page3.tif

source=Trademark Termination#page4.tif

source=Trademark Termination#page5.tif

source=Trademark Termination#page6.tif

**TERMINATION AND RELEASE OF  
TRADEMARK SECURITY AGREEMENT**

This Termination and Release of Trademark Security Agreement (the “Trademark Release”) is made as of May 4, 2017, by **JPMORGAN CHASE BANK, N.A.** in its capacity as administrative agent (the “Administrative Agent”), for Lenders and the other Secured Parties (as defined in the Trademark Security Agreement referred to below) **ACORDA THERAPEUTICS, INC.** (the “Company”), **CIVITAS THERAPEUTICS, INC.** (“Civitas”) and **NEURONEX, INC.** (“Neuronex” and together with Company and Civitas, collectively, the “Grantors”).

WHEREAS, pursuant to that certain Trademark Security Agreement, dated as of June 1, 2016, by and among the Grantors and the Administrative Agent (as amended, amended and restated, restated, supplemented, modified or otherwise in effect prior to the date thereof, the “Trademark Security Agreement”; capitalized terms used herein but not defined herein shall have the meanings ascribed to such terms in the Trademark Security Agreement), each of the Grantors unconditionally granted, assigned, and pledged to the Administrative Agent (for the benefit of the Lenders and the other Secured Parties) a continuing security interest (the “Security Interest”) in all of such Grantor’s right, title and interest in and to the Trademark Collateral;

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on June 10, 2016 at Reel 5811, Frame 0708; and

WHEREAS, the Grantors have requested that the Administrative Agent execute this Trademark Release in order to terminate and release the Administrative Agent’s Security Interest in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged:

1. Release of Lien. The Administrative Agent hereby terminates the Trademark Security Agreement and hereby terminates, cancels and releases the Security Interest and all other liens and security interests that it has in, to and under the Trademark Collateral, including, without limitation, the trademarks set forth on Schedule I attached hereto.

2. Authorization to Record. The Administrative Agent authorizes and requests that the United States Patent and Trademark Office and any applicable government officer record this Trademark Release.

3. Further Assurances. The Administrative Agent agrees to take all further actions and provide to Grantors, their successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of documents or other instruments), reasonably requested by Grantors to more fully and effectively effectuate the purposes of this Trademark Release, at Grantors’ sole cost and expense, and without representation or warranty by the Administrative Agent.

4. Governing Law. This Trademark Release is made under and governed by the laws of the State of New York applicable to contracts made and to be performed entirely within such State, without regard to conflicts of laws principles.

This Trademark Release may be executed in any number of separate counterparts, each of which shall, collectively and separately, constitute one agreement.

[Remainder of Page Intentionally Left Blank]

**IN WITNESS WHEREOF**, the undersigned has caused this Trademark Release to be duly executed as of the date first written above.

**JPMORGAN CHASE BANK, N.A.,**  
as Administrative Agent

By: *Donna DiForio*  
Name: Donna DiForio  
Title: Authorized Officer

**SCHEDULE I**

See attached

Trademark	Status	Country	App Number	Reg. Number	Reg. Date	Reg. Number	Reg. Date	Owner Name
ACORDA THERAPEUTICS	Registered	United States of America	76/111138	2913451	8/17/2000	2913451	12/21/2004	Acorda Therapeutics, Inc.
ACORDA THERAPEUTICS and Design	Registered	United States of America	78/472170	3565849	8/23/2004	3565849	1/20/2009	Acorda Therapeutics, Inc.
ARCUS	Registered	United States of America	85/529823	4217046	1/31/2012	4217046	10/2/2012	Civitas Therapeutics, Inc.
ZANAFLEX (Stylized)	Registered	United States of America	75/186534	2383531	10/15/1996	2383531	9/5/2000	Acorda Therapeutics, Inc.
ZANAFLEX CAPSULES	Registered	United States of America	78/713378	3341341	9/15/2005	3341341	11/20/2007	Acorda Therapeutics, Inc.

**Trademarks (NeurogesX)**

<b>Mark</b>	<b>Status</b>	<b>Country</b>	<b>Serial Number</b>	<b>App. Date</b>	<b>Registration No.</b>	<b>Registration Date</b>	<b>Listed</b>
QUTENZA	Registered	United States of America	77/144,310.	03/29/2007	: 3,719,009	12/01/2009	NeurogesX, Inc
NEUROGESX	Registered	United States of America	78/863,162	04/17/2006	3,878,204	11/16/2010	NeurogesX, Inc
NEUROGESX	Registered	United States of America	78/981,310	04/17/2006	3,786,343	05/04/2010	NeurogesX, Inc